Abbott, Sanofi to interconnect their diabetes monitoring, insulin delivery tech – FierceBiotech

Two of the worlds largest companies in the diabetes space, Abbott and Sanofi, are partnering up to develop tools that integrate their respective blood sugar tracking and insulin delivery technologies.

The end goal is to create a connected device experience for people managing their diabetes, according to the two companies, through new smart insulin pens, smartphone apps for titration and cloud-based software analytics.

The nonexclusive collaboration will aim to combine Abbotts FreeStyle Libre continuous glucose monitoring system with Sanofis background in insulin dosing, into new, compatible devices being developed for regulatory approval within the coming years.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Diabetes can be overwhelming as it is an information-rich condition with various streams of data from multiple devices, Abbott Diabetes Cares senior vice president Jared Watkin said in a statement.

Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their databoth through offering Abbotts digital health tools and by working with other diabetes and technology leaders, Watkin added.

The project will begin with gathering user consent to digitally connect and share data between Abbotts wearable blood sugar sensor and mobile app with Sanofis connected insulin pens and software, currently under development.

RELATED: Sanofi, boosted by partnerships, lays out connected tech ambitions in diabetes

"By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes, said Gustavo Pesquin, senior VP of Sanofis global diabetes and cardiovascular franchise.

Previously, Sanofi helped launch the virtual diabetes clinic Onduo through its joint venture with Verily. It aims to provide connected monitoring devices alongside personalized coaching and advice through a digital platform.

The Big Pharma has also been working with Verily and Sensile Medical to develop an all-in-one insulin patch and pump for patients with Type 2 diabetes. Meanwhile, Abbott has been working to make its FreeStyle Libre platform compatible with Novo Nordisks similarly connected delivery systems.

Link:
Abbott, Sanofi to interconnect their diabetes monitoring, insulin delivery tech - FierceBiotech